BullFrog AI Announces New Commercial Leadership Team to Execute Growth Strategy for its Integrated Pharma AI Platform

GAITHERSBURG, Md., June 02, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, today announced it has appointed commercial technology sales and scientific-focused leaders to support the momentum of the Company's commercial business driven growth strategy.

GlobeNewsWire • Jun 2, 2026

BullFrog AI Regains Compliance with Nasdaq Shareholders' Equity Requirement

GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, today announced that it has received a written notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company has regained compliance with the minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “Stockholders' Equity Rule”).

GlobeNewsWire • Apr 22, 2026

BullFrog AI Announces Participation at AACR Annual Meeting

BullFrog AI team will be available to discuss its end-to-end drug discovery and development workflow at booth 2957 BullFrog AI team will be available to discuss its end-to-end drug discovery and development workflow at booth 2957

GlobeNewsWire • Apr 14, 2026

BullFrog AI Provides Business Update: Strengthened Balance Sheet Supports Continued Execution as Company Aims to Ramp Commercial Activity with Global Pharmaceutical and Biotechnology Partners

GAITHERSBURG, Md., April 13, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (Nasdaq: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence and machine learning to turn complex biomedical data into actionable insights, today issued the following letter to shareholders from Vin Singh, Founder and CEO: Dear Fellow Shareholders, BullFrog AI enters the second quarter of 2026 well-capitalized, at commercial stage, and in active discussions with consequential pharmaceutical and biotechnology organizations.

GlobeNewsWire • Apr 13, 2026

BullFrog AI Shares Surge On Deal With Top Pharma Company For MDD Drug Targets

BullFrog said the agreement will utilize its end-to-end analytical AI platform to accelerate the partner's drug discovery and clinical development program for MDD.

Benzinga • Mar 31, 2026

Bullfrog AI stock offers a rare opportunity for investors to take profit

Bullfrog AI Inc more than doubled on Mar. 30 after announcing a landmark commercial agreement with a “top 5” pharma leader to identify novel therapeutic targets for Major Depressive Disorder. In its press release, BFRG said the pharmaceutical giant has agreed to use its proprietary bfLEAP® platform – providing high-profile validation of its machine-leaning-driven drug discovery tech.

Invezz • Mar 30, 2026

Dow Gains 200 Points; Bullfrog AI Shares Jump

Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) shares shot up 134% to $1.19 after the company announced a commercial agreement with a top five global pharmaceutical company to apply its proprietary bfLEAP platform to identify and prioritize novel drug targets in major depressive disorder.

Benzinga • Mar 30, 2026

BullFrog AI Announces Commercial Agreement with Top 5 Global Pharmaceutical Company to Identify and Prioritize Therapeutic Target in Major Depressive Disorder

GAITHERSBURG, Md., March 30, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, today announced a commercial agreement with a top 5 global pharmaceutical company in 2025 by revenue (“Customer”), to apply the Company's proprietary bfLEAP® platform to identify and prioritize novel drug targets in major depressive disorder (MDD), accelerating the Customer's drug discovery and clinical development program for this indication. The agreement also provides exclusive access to a target candidate. The MDD market was valued at more than $8 billion in 2025 and expected to grow at an average annual rate of nearly 5% to reach in excess of $11 billion by 2032, according to Stellar Market Research.

GlobeNewsWire • Mar 30, 2026

BullFrog AI Unveils bfARENAS™ Scenario-based Decision Engine

Completes end-to-end AI intelligence workflow product with an advanced AI decision tool that clearly defines drug target discovery and clinical trial strategies to build diversified, risk-balanced R&D portfolios Completes end-to-end AI intelligence workflow product with an advanced AI decision tool that clearly defines drug target discovery and clinical trial strategies to build diversified, risk-balanced R&D portfolios

GlobeNewsWire • Mar 25, 2026

BullFrog to Host Webinar on New Precision AI Capability

March 27 webinar at 11 a.m. ET highlights launch of BullFrog AI's new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design March 27 webinar at 11 a.m. ET highlights launch of BullFrog AI's new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design

GlobeNewsWire • Mar 11, 2026